Memantine Grindeks

Memantine hydrochloride, the active ingredient in Memantine Grindeks, is an NMDA receptor antagonist presented as a tablet for oral use. It is used to treat cognitive symptoms of Alzheimer’s disease in adults.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

- Alzheimer’s disease (mild to moderate): improves cognition and daily functioning - Alzheimer’s disease (moderate): may slow functional decline - Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression

Adverse reactions may occur with memantine therapy.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation - Headache: mild to moderate intensity, often resolves with continued use - Constipation: reduced bowel movements, may require dietary adjustment - Fatigue: feeling of tiredness or reduced energy

Serious or Rare Side Effects: - Seizures: rare but may occur, particularly in patients with a seizure history - Cardiac arrhythmia: irregular heart rhythm requiring medical evaluation - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic injury: elevated liver enzymes or hepatitis - Suicidal thoughts: emergent mood changes warrant immediate assessment

Memantine should be used with attention to patient‑specific factors.

- Renal impairment: assess kidney function and consider dose adjustment - History of seizures: monitor closely for new seizure activity - Cardiovascular disease: evaluate risk of arrhythmia before initiating therapy - Concomitant NMDA antagonists: avoid additive neurotoxicity - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant - Store at room temperature: keep in the original container, protect from moisture and direct sunlight

Memantine may interact with several medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Amantadine: combined CNS effects can increase dizziness and confusion - Other NMDA antagonists (e.g., ketamine): additive neurotoxicity risk - Strong CYP450 inhibitors (e.g., quinidine): may raise memantine plasma concentrations

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish memantine’s cognitive benefits - Diuretics: altered renal clearance may affect drug levels - Alcohol: can enhance central nervous system depression and dizziness